Identification of key differentially expressed genes associated with non-small cell lung cancer by bioinformatics analyses

YUBO XIAO\textsuperscript{1,2}, MIN FENG\textsuperscript{3}, HAIYING RAN\textsuperscript{4}, XIAO HAN\textsuperscript{5} and XUEGANG LI\textsuperscript{1}

\textsuperscript{1}Chongqing Productivity Promotion Center for The Modernization of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400715; \textsuperscript{2}Department of Clinical Laboratory, Hunan University of Medicine, Huaihua, Hunan 418000; \textsuperscript{3}Chongqing Key Laboratory of Catalysis and Functional Organic Molecules, College of Environment and Resource, Chongqing Technology and Business University, Chongqing 400067; \textsuperscript{4}Biomedical Analysis Center, Third Military Medical University; \textsuperscript{5}Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400715, P.R. China

Received November 9, 2017; Accepted February 27, 2018

DOI: 10.3892/mmr.2018.8726

Abstract. Increasing evidence has indicated that the abnormal expressions of certain genes serve important roles in tumorigenesis, progression and metastasis. The aim of the present study was to explore the key differentially expressed genes (DEGs) between non-small cell lung cancer (NSCLC) and matched normal lung tissues by analyzing 4 different mRNA microarray datasets downloaded from the Gene Expression Omnibus (GEO) database. In improving the reliability of the bioinformatics analysis, the DEGs in each dataset that met the cut-off criteria (adjust P-value <0.05 and \textit{log}_{2}\textit{fold-change} (FC)\textgreater{}1) were intersected with each other, from which 195 were identified (consisting of 57 upregulated and 138 downregulated DEGs). The GO analysis results revealed that the upregulated DEGs were significantly enriched in various biological processes (BP), including cell cycle, mitosis and cell proliferation while the downregulated DEGs were significantly enriched in angiogenesis and response to drug and cell adhesion. The hub genes, including CCNB1, CCNA2, CEP55, PBK and HMMR, were identified based on the protein-protein interaction (PPI) network. The Kaplan-Meier survival analysis indicated that the high expression level of each of these hub genes correlates with poorer overall survival in all patients with NSCLC, which indicates that they may serve important roles in the progression of NSCLC. In conclusion, the DEGs and hub genes identified in the present study may contribute to the comprehensive understanding of the molecular mechanisms of NSCLC and may be used as diagnostic and prognostic biomarkers as well as molecular targets for the treatment of NSCLC.

Introduction

Lung cancer, which accounts for more than one-tenth of all cancer cases worldwide, is one of the most common types of malignancies and perhaps, the first cause of cancer-related deaths worldwide (1). In China, lung cancer is currently the first most common cancer with more than 733,300 new cases and 610,200 deaths in 2015 (2). Based on histological sub-classification, there are non-small cell lung cancer (NSCLC) and SCLC with approximately 85% of lung cancer patients diagnosed with NSCLC (3).

To date, surgical resection remains the only treatment option for NSCLC (4,5). However, with no specific symptoms associated with the early stage of NCLSC and the lack of accurate and convenient diagnostic methods for its early detection, most patients are diagnosed at the advanced stage of this disease when surgical resection is no longer feasible (6).

With the recent advances in the molecular biology, molecule targeted therapy for NSCLC has equally made significant progress. For example, approximately 10-20% of North American and Western European patients and 30-50% of Asian patients with NSCLC were shown to have mutation of EGFR gene (7). But, with the use of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, these patients were found to respond well (with a response rate of 10%, and an estimated 2-month prolongation in median survival over placebo) (8,9). It was also found that 3-7% of NSCLC patients had an activated ALK gene, but treatment with crizotinib (an ALK inhibitor) elevated their response rate from 10 to 55% (compared to conventional chemotherapy), and increased their 6-month progression-free survival rate to 72% (8). Nevertheless, these situations can only represent a cohort of NSCLC patients and due to drug resistance these targeted therapy agents are often transient.

Moreover, even with the remarkable successes and withdraw that have been obtained in the targeted therapy of...
NSCLC, the precise molecular mechanisms of this disease are still far from being fully understood. Thus, the need to find more potential targets for more effective therapeutic strategies is very paramount.

In order to better understand the DEGs influence on molecular pathogenesis of NSCLC, in this study, we downloaded 4 NSCLC related mRNA datasets from Gene Expression Omnibus (GEO) and identified the DEGs between the NSCLC patients and healthy control samples. Subsequently, we performed Gene Ontology (GO) and protein-protein interaction (PPI) networks analysis so as to study and identify potential key DEGs for the diagnosis and treatment of NSCLC. Further studies on these identified key DEGs can aid a comprehensive understanding of the molecular development of NSCLC and be explored as potential biomarkers for its diagnosis, prognosis, and drug targets.

Materials and methods

Affymetrix microarray data. Series matrix files of the microarray data: GSE21933, GSE33532, GSE44077 and GSE74706 were downloaded from the public GEO database (http://www.ncbi.nlm.nih.gov/geo/), and the probe names based on platforms were annotated to gene symbols according to their corresponding new version of annotation files, such as GPL6254, GPL570, GPL6244 and GPL13497. In each GSE file, we only choose the NSCLC samples and their matched normal samples, and from which we obtained 21 tumor samples and 21 normal samples for GSE21933 (10), 80 tumor samples and 20 normal samples for GSE33532 (11), 65 tumor samples and 65 normal samples for GSE44077 (12) and 18 tumor samples and 18 normal samples for GSE74706 (13) to analyze downstream.

Data pre-processing and differential expression analysis. The original array data of each series were analyzed separately using R software (version 3.4.0) and R packages. In brief: Firstly, background correction and quantile normalization was performed on the raw data using the robust multi-array average (RMA) algorithm in R affy package (14). The differentially expressed proteins (DEGs) between the tumor and normal group samples were then analyzed by the paired t-test based on the limma package in R. Multiple testing was corrected by the Benjamini-Hochberg method to obtain the adjusted P-value (15). Finally, the Genes with adjusted P<0.05 and log2fold-change (FC)>1 were considered to be significant. To further enhance the reliability of the bioinformatics analysis, the overlapping DEGs co-existed in all 4 GSE files were identified using FunRich software version 2.1.2 (http://www.funrich.org) (16).

GO term enrichment analysis. In an attempt to find the potential biological functions associated with these 195 DEGs, the online software DAVID was used to identify the overrepresented GO categories. After GO functional enrichment analysis, as shown in Table 1, the upregulated DEGs were significantly enriched in 18 biological process (BP) terms, which includes mitosis, cell cycle, protein-DNA complex assembly, microtubule-based process and cell proliferation. The downregulated DEGs were also significantly enriched in 16 BP terms, such as cellular response to hormone stimulus, angiogenesis, response to drug and cell adhesion. All these terms are closely related to the tumorigenesis and development.

Hub genes screening from the PPI network. To further investigate the interaction between these 195 DEGs, the
STRING database was used to analysis their PPI networks, and the resulted PPI networks were constructed by Cytoscape. As shown in Fig. 2A, after removing the effect of free protein pairs, we obtained a network with 38 upregulated DEGs, 66 downregulated DEGs and 424 edges.

In addition, in the PPI networks, genes that have strong interactions with many other genes are called ‘hub genes’. Due to their key positions in the PPI network, the hub genes are potential drivers of the diseases status. In order to identify the key tumorigenic genes of NSCLC, the cytoHubba plugin for Cytoscape was used to screen the hub genes among all the DEGs. As shown in Fig. 2B and Table II, we obtained 25 hub genes (the nodes with red or orange colors) that exhibited especially high degree scores (≥19). To our surprise, all these 25 hub genes were upregulated DEGs. The genes G2/mitotic-specific cyclinB1 (CCNB1), CyclinA2 (CCNA2), Centrosomal protein of 55 kDa (CEP55), lymphokine-activated killer T-cell-originated protein kinase (PBK), and hyaluronan mediated motility receptor (HMMR) were selected as the top five hub genes with high connectivity degree. CCNB1, which is also known as cyclin B1, was observed to exhibit the highest degree of connectivity as shown in Table II.

Survival analysis of each hub genes using online tool Kaplan-Meier Plotter. To gain insight into the associations between the hub genes and NSCLC, we did a survival analysis through an online tool Kaplan Meier Plotter, which contains a large number of microarray datasets of lung cancer. As shown in Fig. 3, the survival time of the top five hub genes was significantly separated between the high expression groups and low expression groups in NSCLC patients (P<0.05), with the low expression groups of these 5 hub genes exhibiting a good prognostic effect in NSCLC. Moreover, the remaining 20 hub genes also showed the same trend (data not shown). These imply that the expression levels of the 25 hub genes are significantly associated with clinical prognosis of NSCLC and they may play important roles in the progression of NSCLC.

Discussion

The tumorigenesis, progression and metastasis of lung cancer, like in any other cancer is considered as a very complex process as it involves aberrations of multiple genes and cellular pathways (22). Some DEGs that have multi-interactions with other DEGs are probably core functional genes in promoting the carcinogenesis (23, 24). To improve diagnosis and treatment of NSCLC, it is vitally important to find these abnormal genes and understand their roles in the molecular mechanism of NSCLC. With the development of microarray and high throughput technologies, we have been able to detect the cancer etiology by examining aberrations in whole-genome level as these technologies have been widely used to predict the potential therapeutic targets for cancers (25).

In the present study, using the gene expression profiles of GSE21933, GSE33532, GSE44077 and GSE74706 to screen the co-expressed DEGs between NSCLC and normal samples, a total of 195 DEGs, consisting of 57 upregulated and 138 downregulated DEGs were obtained. The observation that, upregulated DEGs were enriched in BP terms related to mitosis, cell cycle and cell proliferation is consistent with previous knowledge that the functional deficits of cell cycle and cell proliferation regulators are the main causes of tumorigenesis and progression (26). The downregulated DEGs were
Angiogenesis is an essential biological process for tumor growth and metastasis in that, its blockage in tumor tissue has been recognized as a charming strategy to inhibit tumor growth (27). According to Cavallaro and Christofori (28), changes in the expression of cell adhesion molecules could affect the adhesive repertoire of a cell, signal transduction status of cells, the interactions between cells and their environment, and play a crucial role in tumor progression, invasion and metastasis. Our results suggested that these up and downregulated DEGs are involved in these BP and may play important role in the progression of NSCLC.

Table I. Enriched Gene Ontology terms for upregulated and downregulated differentially expressed genes.

A, Upregulated

| Term                | Gene function          | Count | P-value |
|---------------------|------------------------|-------|---------|
| GO:0007067 Mitosis  |                        | 14    | 6.11x10^{-13} |
| GO:0000280 Nuclear division |                    | 14    | 6.11x10^{-13} |
| GO:0000807 M phase of mitotic cell cycle |                | 14    | 7.70x10^{-13} |
| GO:0048285 Organellle fission |                | 14    | 1.02x10^{-12} |
| GO:0000279 M phase |                        | 15    | 6.02x10^{-12} |
| GO:0022403 Cell cycle phase |                | 16    | 9.16x10^{-12} |
| GO:0000278 Mitotic cell cycle |            | 15    | 2.91x10^{-11} |
| GO:0022402 Cell cycle process |            | 16    | 7.21x10^{-10} |
| GO:0007049 Cell cycle |                        | 16    | 5.28x10^{-08} |
| GO:0051301 Cell division |                    | 11    | 8.09x10^{-06} |
| GO:0065004 Protein-DNA complex assembly |               | 5     | 3.22x10^{-04} |
| GO:0007018 Microtubule-based movement |               | 5     | 7.32x10^{-04} |
| GO:0007017 Microtubule-based process |             | 6     | 2.14x10^{-03} |
| GO:0034622 Cellular macromolecular complex assembly |         | 6     | 5.69x10^{-03} |
| GO:0051726 Regulation of cell cycle |                | 6     | 6.72x10^{-03} |
| GO:0034621 Cellular macromolecular complex subunit organization |         | 6     | 9.16x10^{-03} |
| GO:0008283 Cell proliferation |                      | 6     | 2.02x10^{-02} |

B, Downregulated

| Term                        | Gene function                                    | Count | P-value |
|-----------------------------|--------------------------------------------------|-------|---------|
| GO:0032870 Cellular response to hormone stimulus |                          | 6     | 1.73x10^{-05} |
| GO:0001525 Angiogenesis     |                                                  | 10    | 3.41x10^{-05} |
| GO:0050900 Leukocyte migration |                                              | 7     | 2.53x10^{-04} |
| GO:0030336 Negative regulation of cell migration |                    | 6     | 6.18x10^{-04} |
| GO:0042493 Response to drug |                                              | 9     | 1.62x10^{-03} |
| GO:0007165 Signal transduction |                                            | 18    | 3.98x10^{-03} |
| GO:0007155 Cell adhesion    |                                                 | 10    | 5.99x10^{-03} |
| GO:0016337 Single organismal cell-cell adhesion |                        | 5     | 6.12x10^{-03} |
| GO:0002576 Platelet degranulation |                                  | 5     | 6.56x10^{-03} |
| GO:0006898 Receptor-mediated endocytosis |                           | 6     | 1.12x10^{-02} |
| GO:0043065 Positive regulation of apoptotic process |                    | 7     | 2.15x10^{-02} |
| GO:0018108 Peptidyl-tyrosine phosphorylation |                          | 5     | 2.48x10^{-02} |
| GO:0045893 Positive regulation of transcription, DNA-templated |                     | 9     | 3.28x10^{-02} |
| GO:0045087 Innate immune response |                               | 8     | 3.61x10^{-02} |
| GO:0006810 Transport        |                                                 | 7     | 4.02x10^{-02} |

Count, the number of enriched genes in each term.
but not all types of NSCLC. They showed that, different subtypes of NSCLC are not only biologically different but also showed variation in their CCNB1 expressions. Of all the histological subtypes examined, overexpression of CCNB1...
Table II. Statistical results of connectivity degrees of the hub genes in the PPI network.

| Gene     | Degree | Gene     | Degree |
|----------|--------|----------|--------|
| CCNB1    | 28     | KIF11    | 24     |
| CCNA2    | 27     | KIF20A   | 24     |
| CEP55    | 25     | CCNB2    | 24     |
| PBK      | 25     | CENPF    | 24     |
| HMMR     | 25     | TPX2     | 24     |
| DTL      | 24     | MKI67    | 23     |
| KIAA0101 | 24     | KIF4A    | 23     |
| MELK     | 24     | CENPE    | 23     |
| ANLN     | 24     | AURKA    | 23     |
| KIF14    | 24     | HELLS    | 21     |
| CDKN3    | 24     | CKAP2L   | 19     |
| ASPM     | 24     | UBE2T    | 19     |
| NUF2     | 24     |          |        |

PPI, protein-protein interaction.

was more frequently observed in the squamous cell carcinoma (SCC) subtypes. This overexpression was also reported to affects patient survival time and might be an adverse prognostic marker for SCC-subtype NSCLC patients (31). While our work establishes CCNB1 as a top hub gene in NSCLC in agreement with these reports, it did not specify the subtypes, which could be a possible limitation to our analysis. The second hub gene CCNA2, encoding cyclins controls both the G1/S and the G2/M transition of the cell cycle (32). Its protein expression was found to be elevated in variety of tumors, including breast, liver, prostate and lung cancers, and appears to be a prognostic marker in prediction of survival or early relapse (33). The third hub gene CEP55 (also known as c10orf3 and FLJ10540), a pivotal component of cytokinesis, is associated with the PI3K/AKT pathway activation via an interaction with the catalytic subunit of PI3K (34). CEP55 overexpression is highly correlated with carcinogenesis across multiple cancer types including lung, breast, liver, and colon cancers and has been identified as a member of several prognostic 'gene signatures' for cancer (35). Tao et al (36) has reported that ectopic expression of CEP55 induces tumorigenesis in nude mice, while its knockdown in gastric cancer cells suppressed cellular proliferation by inducing G2/M phase arrest, indicating its potential as an anti-tumor target. PBK also known as TOPK, was found to play an important role in tumor formation and progression. Its high expression level was detectable in the majority of lung cancer tissues and cell lines, but not in normal tissues (37-40). Overexpression of PBK was reported to promote a PI3K/AKT-dependent cell migration (5). Lei et al (40), suggested that PBK expression was positively correlated with Ki67 and p53 expression, and could be used as an independent prognostic factor in NSCLC. Another hub gene which we found to be hyper-expressed in NSCLC is HMMR, a multifunctional oncogene. Its high expression level, which was also found in breast cancer, is associated with poor disease outcome (41). Recent studies have deciphered that HMMR could regulate cell proliferation, survival, and migration via forming a complex with CD44 (a well-known cancer stem cell marker) and hyaluronan (a key component of the microenvironment of most malignant tumors) (42). In this study, HMMR showed a strong interaction with each of the top five hub genes, which indicates their joint functions in NSCLC, although further investigations are still needed to clarify underlying biological associations between HMMR and NSCLC. All these reports indicate that CCNB1, CCNA2, CEP55, PBK, and HMMR are involved in the pathogenesis of malignant tumors mainly by affecting cell cycle and mitosis. This is consistent with our findings. Furthermore, the Kaplan Meier Plotter survival analysis from our study demonstrated that mRNA expression levels of these five hub genes, as well as the remaining 20 hub genes, were significantly associated with clinical prognosis of lung cancer. While these could imply their roles in the progression of NSCLC thereby making them a potential target for its diagnosis and treatment, further experimental verification of the clinical significance of each hub gene and its subtypes is still necessary.

In summary, using the bioinformatics, we have provided information on the DEGs and hub genes that may be involved in NSCLC. This analysis is, however, limited in that it does not capture the expression of these genes in the different NSCLC subtypes. Another limitation of this work is that, in reducing the number of false positive DEGs, we obtained co-expressed DEGs among 4 different NSCLC associated microarray datasets. By this, many likely important genes might have been lost. While our work showed the benefit and usefulness of microarray analysis in bringing out the DEGs and hub genes that can be potential diagnostic and treatment targets of NSCLC, the need for improved analysis and prospective clinical studies is still imperative. Albeit, this study can contribute to the overall understanding of the underlying molecular mechanisms of NSCLC and serve as guide to subsequent experimental studies.

Acknowledgements

Not applicable.

Funding

This study was financially supported by Fundamental Research Funds for the Central Universities (grant no. XDIK2017D143), Fundamental Research Program of Hunan University of Medicine (grant no. 2014KY03) and Science and Technology Plan Projects of Huaihua (2014-17). Funding was also received from Chongqing Science and Technology Commission (grant no. cstc2015jcyjA0061), Chongqing Educational Ministry (grant no. KJ1500637) and The National Key Research and Development Program of China for Traditional Chinese Medicine Modernization (grant nos. 2017YFC1702600 and 2017YFC1702605).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.
Authors' contributions

YBX and XGL conceived and designed the study. YBX, MF, HYR and KH performed the data analysis. YBX and HYR wrote the paper. YBX, XGL, MF, HYR and XH reviewed and edited the manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Semenova EA, Nagel R and Berns A: Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev 29: 1447-1462, 2015.
2. Chen W, Zheng R, Baade PD, Feuer EJ, He J, Zhang J, Zou K, Tan D, Xu L,楼层 Z, et al: Cancer statistics in China, 2015. CA Cancer J Clin 66: 115-132, 2016.
3. Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med 359: 1367-1380, 2008.
4. Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacka M and Rosell R: Pharmacogenomics in non-small-cell lung cancer chemotherapy, Adv Drug Deliv Rev 61: 408-417, 2009.
5. Shih MC, Chen JY, Wu YC, Jan HY, Yang BM, Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M and Lai JM: TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 31: 2389-2400, 2012.
6. Keith RL and Miller YE: Lung cancer chemoprevention: Current status and future prospects. Nat Rev Clin Oncol 10: 334-343, 2013.
7. Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE and Jänne PA: Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 8: 179-184, 2013.
8. Gerber DE and Minna JD: ALK inhibition for non-small cell lung cancer: From discovery to therapy in record time. Cancer cell 18: 548-551, 2010.
9. Janku F, Stewart DJ and Kurzrock R: Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 7: 401-414, 2010.
10. Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, et al: The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer 12: 235, 2012.
11. Meister M, Belousov A, Xu EC, Schnabel PA, Warth A, Hoffmann H, Dienemann H, Riedlinger J, Bodenmüller H, Zolg W, et al: Intra-tumor heterogeneity of gene expression information is through the activation of PI3K-AKT pathway. Cancer Res 2014.
12. Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Cavallaro U, Jänne PA, Pasquali G, Giovannetti E, Crea F, Altavilla G, Del Tacka M and Rosell R: Pharmacogenomics in non-small-cell lung cancer chemotherapy, Adv Drug Deliv Rev 61: 408-417, 2009.
13. Marwit S, Depner S, Dvornikov D, Merkle R, Szczygiel M, Müller-Decker K, Lucarelli P, Wäsch M, Mairbäurl H, Rabe KF, et al: Downregulation of the TGFβ Pseudoreceptor BAMBI in non-small cell lung cancer enhances TGFβ signaling and invasion. Cancer Res 76: 3785-3801, 2016.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003.
15. Benjamin Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc Ser B 57: 289-300, 1995.
16. Patham M, Keerthikumar S, Dave CS, Gangoda L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, et al: FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics 15: 2597-2601, 2015.
17. Gene Ontology Consortium: The gene ontology (GO) project in 2006. Nucleic Acids Res 34 (Database Issue): D322-D326, 2006.
18. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery, and generated database. Genome Biol 4: P3, 2003.
19. Szklarczyk D, Morris RJ, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45 (D1): D362-D368, 2017.
20. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504, 2003.
21. Szász AM, Lánzczky A, Nagy A, Fürster S, Hark K, Green JE, Boussioutas A, Basuttil R, Szabó A and Györffy B: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 7: 49322-49333, 2016.
22. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 799-799, 2004.
23. Saito M, Shiraiishi K, Kunitoh H, Takenoshita S, Yokota J and Kohno T: Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci 107: 713-720, 2016.
24. Cardarella S and Johnson BE: The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 188: 770-775, 2013.
25. Liang B, Li C and Zhao J: Identification of key pathways and genes in colorectal cancer using bioinformatics analysis. Med Oncol 33: 111, 2016.
26. Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature 432: 316-323, 2004.
27. Feng X, Oístad W and Hawkins D: Antiangiogenesis therapy: A new strategy for cancer treatment. US Pharm Sci 35 (Oncology Suppl): S4-S9, 2010.
28. Cavallaro U and Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118-132, 2004.
29. Petri ET, Errico A, Escobedo L, Hunt T and Basavappa R: The crystal structure of human cyclin B. Cell Cycle 6: 1342-1349, 2007.
30. Yuan J, Yan R, Krümer A, Eckerdt F, Roller M, Kaufmann M and Strebhardt K: Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 23: 8549-853, 2004.
31. Soria JC, Jiang SJ, Khuri FR, Hassan K, Liu D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60: 4000-4004, 2000.
32. Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971, 1992.
33. Yam CH, Fung TK and Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326, 2002.
34. Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ, Tsou AP, Lee YC, Lin TC, Hsu SL, Lin YH, et al: FLJ10540-elicited cell transformation, and integrated discovery and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 4: P3, 2003.
35. Jeffery J, Sinha D, Srihari S, Kalimutho M and Khanna K: Beyond cytokines: The emerging roles of CEP55 in tumorigenesis. Oncogene 35: 683-690, 2016.
36. Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W, Xie K, Tang J, Zhang X, Wang L and Xu Z: CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol 35: 4389-4399, 2014.
37. Zhu F, ZykoVA TA, Kang BS, Wang Z, Ebeling MC, Abe Y, Miyakawa Y, Bode AM and Dong Z: Bidirectional signals transmitted by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology 135: 219-231, 2007.
38. ZykoVA TA, Zhu F, Lu C, Higgins L, Tatsuki Y, Abe Y, Bode AM and Dong Z: Lymphokine-activated killer T-cell-derived protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin Cancer Res 12: 6884-6893, 2006.
39. Zlobec I, Molinari F, Kovac M, Bihl MP, Altermatt HJ, Diebold J, Frick H, Germer M, Horcic M, Montani M, et al: Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Br J Cancer 102: 151-161, 2010.

40. Lei B, Liu S, Qi W, Zhao Y, Li Y, Lin N, Xu X, Zhi C, Mei J, Yan Z, et al: PBK/TOPK expression in non-small-cell lung cancer: Its correlation and prognostic significance with Ki67 and p53 expression. Histopathology 63: 696-703, 2013.

41. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, et al: Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 39: 1338-1349, 2007.

42. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J and Turley EA: The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 282: 16667-16680, 2007.